A drug being developed by Bristol-Meyers Squibb saved more lives than Warfarin in a major stroke prevention study.
Researchers say the drug called Apixaban reduced the risk of stroke in patients with atrial fibrillation by 21 percent. It also lowered by 31 percent the incidence of bleeding, which can be serious side effect of Warfarin.
The twice a day pill also cut patient's risk of death by 11 percent during a two year follow up study. The medication's brand name is Eliquis and it's one of several new anti-clotting drugs in the race to replace Warfarin.
Study results are in the New England Journal of Medicine.
